Allelic imbalance in the MSK-IMPACT Clinical Sequencing Cohort
Ontology highlight
ABSTRACT:
INSTRUMENT(S): -
ORGANISM(S): Homo Sapiens
SUBMITTER: MSKCC
PROVIDER: PRJEB28874 | EVA | 2020-10-01
REPOSITORIES: EVA
Similar Datasets
Project description:Identifying genes where a variant allele is preferentially expressed in tumors could lead to a better understanding of cancer biology and optimization of targeted therapy. However, tumor sample heterogeneity complicates standard approaches for detecting preferential allele expression. We therefore developed a novel approach combining genome and transcriptome sequencing data from the same sample that corrects for sample heterogeneity and identifies significant preferentially expressed alleles. We applied this analysis to epithelial ovarian cancer samples consisting of matched primary ovary and peritoneum and lymph node metastasis. We find that preferentially expressed variant alleles include germline and somatic variants, are shared at a relatively high frequency between patients and are in gene networks known to be involved in cancer processes. Analysis at a patient level identifies patient-specific preferentially expressed alleles in genes that are targets for known drugs. Analysis at a site level identifies patterns of site specific preferential allele expression with similar pathways being impacted in the primary and metastasis sites. We conclude that genes with preferentially expressed variant alleles can act as cancer drivers and that targeting those alleles could lead to new therapeutic strategies. Three cancer patients, three tumor samples per patient from different sites, two normal tissue samples from two different patients, four cell lines.
2015-12-12 | E-GEOD-75935 | biostudies-arrayexpress
Project description:Identifying genes where a variant allele is preferentially expressed in tumors could lead to a better understanding of cancer biology and optimization of targeted therapy. However, tumor sample heterogeneity complicates standard approaches for detecting preferential allele expression. We therefore developed a novel approach combining genome and transcriptome sequencing data from the same sample that corrects for sample heterogeneity and identifies significant preferentially expressed alleles. We applied this analysis to epithelial ovarian cancer samples consisting of matched primary ovary and peritoneum and lymph node metastasis. We find that preferentially expressed variant alleles include germline and somatic variants, are shared at a relatively high frequency between patients and are in gene networks known to be involved in cancer processes. Analysis at a patient level identifies patient-specific preferentially expressed alleles in genes that are targets for known drugs. Analysis at a site level identifies patterns of site specific preferential allele expression with similar pathways being impacted in the primary and metastasis sites. We conclude that genes with preferentially expressed variant alleles can act as cancer drivers and that targeting those alleles could lead to new therapeutic strategies.
2015-12-12 | GSE75935 | GEO
Project description:Clinical Sequencing: Clinical Cancer Sequencing
| PRJNA233540 | ENA
Project description:RNA sequencing and other experimental methods producing large amounts of data are increasingly dominant in molecular biology. However, the noise properties of these techniques are not fully appreciated. We assessed how reproducible are the measurements of allele-specific expression between replicate RNA-seq experiments from the same RNA sample. Surprisingly, estimates of allelic imbalance (AI) varied between technical replicates up to 8-fold higher than expected from commonly applied noise models. We show that AI overdispersion substantially varies between replicates and experimental series, appears to arise during the construction of sequencing libraries, and can be measured by comparing technical replicates. We demonstrate that compensation for AI overdispersion greatly reduces technical variation and enables reliable differential analysis of allele-specific expression across samples and across experiments. Conversely, not taking AI overdispersion into account can lead to a substantial number of false positives in analysis of allele-specific gene expression.
2021-03-26 | GSE143310 | GEO
Project description:Primary outcome(s): cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency
| 2646701 | ecrin-mdr-crc
Project description:KRAS mutations in renal cell carcinoma (RCC) are rare and are associated with the histologic subtype "papillary renal neoplasm with reverse polarity" (PRNRP). Despite this association, the broader clinical and molecular implications of KRAS mutation in RCC are not well understood. This study aimed to characterize the clinical and molecular features of KRAS-mutated RCC. KRAS-mutant RCC patients were identified within the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) and The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP) repository. Fraction and allele-specific copy number estimates from tumor sequencing (FACETS) was performed to obtain copy number alterations. Available samples were used for immunohistochemistry and RNA-sequencing analysis. Seventeen patients were included. Three distinct KRAS-mutant RCC subtypes were identified: KRAS-mutant PRCC (35%), KRAS-mutant URCC (35%), and PRNRP (29%). Seven patients (41%) had metastatic disease; none were PRNRP. RNAseq-based deconvolution analysis revealed that PRNRP had enrichment in distal nephron components, whereas KRAS-mutant PRCC was enriched in proximal tubule cells (p = 0.02). IHC staining of L1CAM was positive in PRNRP but negative in KRAS-mutant PRCC, supporting their distinct cell-of-origin phenotypes. This study is limited by its cohort size, which influences the availability of tissue samples. PRNRP represents a distinct KRAS-mutant RCC subtype with unique metabolic and genomic features linked to its distal nephron origin. This contrasts with the genomic complexity and aggressive clinical behavior observed in KRAS-mutant PRCC and URCC, highlighting the need for subtype-specific diagnostic criteria and therapeutic strategies.
2025-12-17 | GSE309610 | GEO
Project description:Inborn errors of immunity (IEIs) are genetic disorders that underlie susceptibility to infection, autoimmunity, autoinflammation, allergy, and/or malignancy. Incomplete penetrance is common among IEIs despite their monogenic basis. Herein we investigate the contribution of autosomal random monoallelic expression (aRMAE), a somatic commitment to expression of one allele, to phenotypic variability observed in families with IEIs. Using a clonal primary T cell system to assess aRMAE status of genes in healthy individuals, we find 4.30% of IEI genes and 5.20% of all genes undergo aRMAE. Perturbing H3K27me3 and DNA methylation alters allele expression commitment, supporting two proposed mechanisms for regulation of aRMAE. We tested PBMCs from individuals sharing genetic lesions but with discordant clinical phenotypes in seven families with different IEIs for aRMAE. Among relatives heterozygous for a mutation in PLCG2, an antibody deficiency phenotype corresponds with selective mutant allele expression in B cells. In contrast, among relatives heterozygous for a mutation in JAK1, the unaffected carrier T cells predominantly expressed the wild-type JAK1 allele, while the affected carrier T cells exhibited biallelic expression. Selective expression of a single allele was documented in phenotypically discordant family members carrying an AD Loss-of-function (LoF) mutation in STAT1, CARD11, as well as gain-of-function (GoF) mutations in STAT1. This study highlights the importance of not only considering genotype but also the “transcriptotype” in the analyses of the penetrance and expressivity of monogenic disorders.
2024-10-23 | GSE279855 | GEO
Project description:Investigation of non-synonymous mutation as a major driver for cancer is essential for discovery of biomarkers and therapeutics. Although, many cancer-associated mutations have been identified through genomics, there is a poor understanding of how they manifest in the proteome. In fact, detection of mutation derived peptides is confounded by technical and biological factors. In this study cancer associated mutations from the COSMIC database were integrated into proteins, to generate cell line specific sequence databases. We used a robust workflow for high-throughput processing of 375 cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) to identify mutant peptides and generate PRIDE compatible mzTab results. This includes a peptide to genome mapping tool, PepGenome, allowing targeted mapping of mutant peptides. Examining the allelic paired non-mutant reference peptides, we were able to profile significantly more potential mutant peptides and determine allelic biases in the expression and observation of mutant peptides. We present quantification, genomic mapping, and evaluation of 1,336 cancer associated mutant peptides and infer protein allelic bias for 31,219 mutations in. We highlight the problems faced in detecting and characterising mutant peptides by mass spectrometry and show that allelic bias plays a significant role in suppressing the expression of mutant proteoforms.
2025-12-17 | PXD044389 | Pride
Project description: Not available
| S-EPMC6220258 | biostudies-literature
Project description:KRAS mutations constitute one of the most prevalent and therapeutically relevant oncogenic drivers in human cancers. Clinical and epidemiological data suggest association between specific KRAS alleles, therapeutic response, and patient outcomes, however, direct experimental validation of these relationships has been limited. In this study, we employed genetically engineered mouse models (GEMMs) to investigate the differential impacts of three most common KRAS Gly12 mutations (KRASG12C, KRASG12D, and KRASG12V) in the context of intestinal homeostasis and tumorigenesis. Although tumors developing from different KRAS Gly12 mutants exhibited no significant histological differences, their effects on survival outcomes of tumor bearing mice and therapeutic response displayed pronounced allele-specific differences. Our transcriptomic analyses revealed both allele-agnostic and allele specific transcriptional programs driven by KRAS Gly12 mutations in colon tumors. The allele-agnostic signature was characterized by enrichment of gene sets associated with MAPK signaling, receptor tyrosine kinase pathways, and immune-modulating pathways, compared to KRAS WT tumors. In contrast, allele-specific signature revealed unique OXPHOS pathway upregulation in KrasG12D tumors and marked enrichment of Notch and Wnt/-catenin signaling pathways in KrasG12C tumors. Inhibition of these pathways, in combination with KRASG12C inhibitor led to either addictive or synergistic reduction in tumor cell viability, in allele-specific manner. Collectively, these findings underscore the importance of understanding the distinct biological effects of KRAS Gly12 mutants on colon tumorigenesis and highlight the therapeutic relevance of allele specific signaling dependencies in colorectal cancer. These results provide key mechanistic insights and provide a foundation for the development of effective, allele-informed therapeutic strategies for KRAS mutant cancers.
2025-07-02 | GSE301459 | GEO